Venturi Masks Market By Product Type (Disposable Venturi Masks, Reusable Venturi Masks); By Application (Chronic Obstructive Pulmonary Disease, Asthma, Pneumonia, Postoperative Oxygen Therapy, Other Respiratory Conditions); By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Homecare Settings, Emergency Medical Services); By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Venturi Masks Market: Controlled-Oxygen Protocols Drive Recurring Demand for Precision Respiratory Consumables

The Global Venturi Masks Market was valued at USD 0.48 billion in 2025 and is projected to reach USD 0.73 billion by 2032, expanding at a CAGR of 6.1% during 2026–2032, according to Strategic Market Research.

 

A Venturi mask delivers a precise, fixed oxygen concentration through color-coded or adjustable air-entrainment valves using the Bernoulli principle. The FDA classifies low-concentration Venturi oxygen masks under product code BYF and 21 CFR 868.5600. The FDA-approved mechanism of action (MOA) is based on controlled oxygen entrainment, where pressurized oxygen flows through a narrow jet, creating a pressure drop that draws in a predetermined amount of room air through calibrated ports, resulting in a fixed and predictable inspired oxygen concentration (FiO₂). These masks mix oxygen with entrained room air and are widely used for patients with chronic obstructive pulmonary disease and other conditions associated with carbon dioxide retention.

 

Clinical protocols remain the strongest demand driver. British Thoracic Society guidance recommends maintaining oxygen saturation between 88–92% in patients at risk of hypercapnic respiratory failure, with 24% and 28% Venturi masks commonly used while blood-gas results are pending. This is commercially significant because COPD affects an estimated 390 million people globally and an age-adjusted 3.8% of U.S. adults. Despite competition from nasal cannulas and high-flow oxygen systems, Venturi masks remain standard equipment in emergency departments, wards, postoperative units and ambulances because of their low cost, simple operation and fixed-concentration performance.

 

COPD Burden Sustains the Core Market

COPD remains the main clinical foundation for Venturi-mask demand and represented 37.0% of total application revenue in 2025. The CDC reported that diagnosed COPD affected 3.8% of U.S. adults in 2023, increasing from 0.4% among people aged 18–24 to 10.5% among those aged 75 and older. COPD was also the fifth-leading cause of death in the United States in 2023, accounting for 141,733 deaths.

Ageing populations are commercially important because older adults are more likely to experience COPD exacerbations, pneumonia, postoperative respiratory complications and multiple conditions that complicate oxygen administration. Venturi-mask use also extends to bronchiectasis, neuromuscular disorders, severe obesity, chest-wall conditions and previous hypercapnic respiratory failure. These conditions are included within the broader respiratory-conditions segment, which held 10.0% of the market in 2025 and is growing faster than the core COPD application.

COPD is the main driver of demand, affecting an estimated 213–391 million people globally and causing around 3.4–3.7 million deaths each year, making it the third leading cause of death worldwide. The burden is expected to rise further, potentially reaching ~600 million cases by 2050 due to ageing populations and air pollution.

In the United States, over 15 million people are diagnosed, though true prevalence may be closer to 24–30 million due to underdiagnosis. COPD causes about 141,000 deaths annually and generates more than $24 billion in direct healthcare costs.

In Asia-Pacific, there are roughly 70 million patients—about one-third of the global total—with the highest death rates driven largely by air pollution and biomass fuel exposure rather than smoking alone.

 

Precision Oxygen Delivery Systems: Disposable vs Reusable Venturi Mask Dynamics

Disposable Venturi Masks Dominate Market Demand Through Infection Control

Disposable Venturi masks dominated the product market with a 72.0% share in 2025, valued at USD 0.3456 billion. The segment is projected to reach USD 0.5475 billion by 2032 at a CAGR of 6.79%, outperforming reusable masks.

Their dominance is linked to single-patient use, which allows hospitals to dispose of the complete mask set after treatment. This reduces cleaning and sterilisation requirements and supports infection-control practices across emergency rooms, wards, ambulances and recovery units. Public procurement also favours individually packaged disposable formats. A 2026 Northern Ireland oxygen-therapy framework included Venturi masks as a separate procurement lot, while WHO’s 2021 support to Nepal supplied 24,000 Venturi-mask sets alongside more than 2,000 oxygen concentrators.

The segment grows faster because hospitals prioritise immediate availability, lower handling effort and reduced cross-patient contamination risk. Its 72.0% share also gives disposable-product suppliers the strongest exposure to recurring replenishment orders, although large-volume tenders continue to place pressure on unit pricing.

 

Reusable Venturi Masks Retain Use in Cost-Sensitive Settings

Reusable Venturi masks held 28.0% of the market in 2025, valued at USD 0.1344 billion, and are projected to reach USD 0.1825 billion by 2032 at a CAGR of 4.47%.

Demand is concentrated in hospitals and facilities with established sterilisation systems that aim to reduce recurring consumable costs. Reusable products are also used in training and selected homecare environments where disposable supply is limited. Growth remains slower because cleaning, inspection and performance verification increase labour and reprocessing costs. The segment also competes with disposable multi-vent kits that simplify inventory management without requiring reuse.

 

Application Landscape and Growth Drivers

COPD Anchors the Largest Revenue Stream

The COPD segment held the largest application share at 37.0% in 2025, generating USD 0.1776 billion. Revenue is projected to reach USD 0.2628 billion by 2032 at a CAGR of 5.76%.

COPD leads because patients at risk of hypercapnic respiratory failure require controlled oxygen. British Thoracic Society guidelines recommend an 88–92% saturation target while blood-gas results are pending, giving Venturi masks a clear role through their fixed concentration settings. Growth is moderate because the masks compete with nasal cannulas, non-invasive ventilation and high-flow oxygen across different stages of care.

 

Asthma Supports Acute-Care Demand

Asthma accounted for 19.0% of the market in 2025, equal to USD 0.0912 billion. The segment is forecast to reach USD 0.1314 billion by 2032 at a CAGR of 5.36%.

Demand comes mainly from severe exacerbations managed in hospitals and emergency departments. Venturi masks are selected when controlled oxygen is required, while nasal cannulas, simple masks and high-concentration devices serve other severity levels. These alternatives keep asthma below COPD in market share and limit growth to 5.36%.

 

Pneumonia Maintains Recurring Hospital Use

Pneumonia represented 18.0% of the market in 2025, with revenue of USD 0.0864 billion. The segment is expected to reach USD 0.1241 billion by 2032 at a CAGR of 5.31%.

Demand is concentrated among patients needing controlled oxygen in acute care, particularly older adults and people with underlying COPD. Seasonal infection peaks and hospital admissions support recurring use, while mild cases commonly use nasal cannulas and severe cases require high-flow oxygen, non-invasive ventilation or mechanical ventilation.

 

Postoperative Oxygen Therapy Records the Fastest Application Growth

Postoperative oxygen therapy accounted for 16.0% of the market in 2025, generating USD 0.0768 billion. It is projected to reach USD 0.1314 billion by 2032 at the highest application CAGR of 7.97%.

Growth is supported by rising surgical volumes in hospitals and ambulatory surgical centres, where oxygen is frequently administered after anaesthesia or sedation. Medicare-certified ambulatory surgical centres in the United States increased by 2.2% to 6,436 facilities in 2024, including 248 newly opened centres. As procedures shift toward outpatient settings, demand for short-duration, controlled oxygen delivery is increasing faster than in the mature COPD segment.

 

Broader Respiratory Conditions Gain Momentum

Other respiratory conditions held 10.0% of the market in 2025, equal to USD 0.0480 billion. Revenue is forecast to reach USD 0.0803 billion by 2032 at a CAGR of 7.63%.

This segment includes bronchiectasis, chest-wall disorders, obesity-related hypoventilation and neuromuscular conditions. Its 7.63% CAGR reflects broader clinical recognition that hypercapnic respiratory risk extends beyond COPD and requires controlled oxygen across medical wards, ambulances and emergency departments.

 

Care Delivery Channels Driving Venturi Mask Utilisation

Hospitals and Clinics Remain the Primary End Users

Hospitals and clinics dominated the market with a 58.0% share in 2025, generating USD 0.2784 billion. The segment is projected to reach USD 0.4015 billion by 2032 at a CAGR of 5.37%.

This leadership reflects high volumes of COPD, pneumonia, postoperative and emergency respiratory cases. The American Hospital Association reports about 6,100 U.S. hospitals and 35.7 million annual admissions, supporting steady replenishment of oxygen-delivery consumables. Hospitals generally procure Venturi masks through distributors and group contracts alongside tubing, cannulas and related respiratory products.

 

Ambulatory Surgical Centres Expand Postoperative Demand

Ambulatory surgical centres represented 14.0% of the market in 2025, generating USD 0.0672 billion. Revenue is forecast to reach USD 0.1095 billion by 2032 at a CAGR of 7.22%.

The segment benefits from the movement of procedures outside inpatient hospitals. These facilities use Venturi masks during recovery, unexpected desaturation and respiratory events in patients with underlying disease. Cost-sensitive purchasing favours disposable products, compact case sizes and multi-concentration options.

 

Homecare Is the Fastest-Growing End-User Segment

Homecare settings accounted for 18.0% of the market in 2025, equal to USD 0.0864 billion. The segment is projected to reach USD 0.1533 billion by 2032 at the highest end-user CAGR of 8.54%.

Growth is driven by wider use of home oxygen therapy and community-based care. CMS supports home oxygen equipment under the durable medical equipment benefit when medical criteria are met. Nasal cannulas remain the primary interface for long-duration oxygen, while Venturi masks serve selected patients requiring controlled concentrations, particularly those at risk of carbon dioxide retention. Expansion depends on caregiver training, clear flow instructions, comfort and compatibility with concentrators.

 

Emergency Medical Services Retain a Defined Role

Emergency medical services held 10.0% of the market in 2025, generating USD 0.0480 billion. Revenue is expected to reach USD 0.0657 billion by 2032 at a CAGR of 4.59%, the slowest end-user growth rate.

Ambulances carry several oxygen interfaces because patient needs are unknown before assessment. Venturi masks are mainly used for suspected COPD or hypercapnia risk, while nasal cannulas and non-rebreather masks cover other oxygen requirements. Limited storage and standardisation around multipurpose products constrain faster growth.

 

Institutional Procurement Shapes Product Selection

Venturi masks have a low unit value but are purchased repeatedly in large quantities. Institutional procurement therefore strongly influences supplier competition and market share, particularly because hospitals and clinics account for 58.0% of total revenue and disposable masks represent 72.0% of product demand.

Healthcare systems typically procure Venturi masks through centralised hospital contracts, group purchasing organisations and regional tenders. These agreements frequently bundle masks with nasal cannulas, non-rebreathing masks, tubing and humidification systems, favouring suppliers with broad respiratory portfolios.

Procurement decisions increasingly consider clinical compliance, product consistency, supply reliability and sustainability alongside price. Accurate oxygen delivery depends on consistent valve performance and standardised manufacturing. Suppliers must therefore maintain stable production, efficient logistics and dependable distributor relationships, as small design differences matter less than the ability to fulfil high-volume contracts without disruption.

 

Regulatory Requirements Protect Product Consistency

The FDA classifies low-concentration Venturi oxygen masks as Class I devices under 21 CFR 868.5600 and product code BYF. The classification simplifies entry compared with ventilators and oxygen blenders, while manufacturers remain responsible for quality, labelling, registration and complaint handling.

Because oxygen delivery depends on valve accuracy and airflow control, hospitals favour masks with clear concentration markings, reliable colour coding and secure connectors. The relatively low regulatory barrier supports a fragmented supplier base, but large healthcare systems generally prefer established manufacturers with proven quality systems and complete respiratory portfolios.

 

Global Regional Demand Landscape and Growth Dynamics

North America Maintains Market Leadership

North America held the largest regional share at 36.0% in 2025, generating USD 0.1728 billion. Revenue is projected to reach USD 0.2482 billion by 2032 at a CAGR of 5.31%.

The region leads because of its large hospital base, established emergency oxygen protocols and mature distributor networks. COPD prevalence reached 3.8% among U.S. adults in 2023 and 10.5% among those aged 75 and older. Growth is moderate because the market is mature and depends mainly on replacement demand, outpatient procedures and incremental product upgrades.

 

Europe Remains a Key Revenue Hub

Europe accounted for 28.0% of the market in 2025, valued at USD 0.1344 billion. It is projected to reach USD 0.1971 billion by 2032 at a CAGR of 5.62%.

Demand is supported by controlled-oxygen guidelines and a high chronic respiratory disease burden. WHO reported 81.7 million people living with chronic respiratory diseases in Europe, contributing to nearly 400,000 deaths annually. Structured tenders in Northern Ireland and Scotland prioritise quality, pricing, service and sustainability, favouring established suppliers with local distribution and products such as Intersurgical’s non-PVC EcoLite range.

 

Asia-Pacific Is the Fastest-Growing Region

Asia-Pacific represented 24.0% of the market in 2025, generating USD 0.1152 billion. Revenue is expected to reach USD 0.1971 billion by 2032 at the highest regional CAGR of 7.97%.

Growth is driven by hospital expansion, improving oxygen access and the transition from emergency supply to structured national procurement. WHO’s Nepal program, which distributed more than 2,000 concentrators and 24,000 Venturi-mask sets, illustrates how oxygen-infrastructure investment creates immediate demand for interfaces and tubing. International suppliers lead regulated urban tenders, while local manufacturers compete through price and faster delivery.

 

Latin America Expands Steadily

Latin America held 7.0% of the market in 2025, valued at USD 0.0336 billion. Revenue is projected to reach USD 0.0511 billion by 2032 at a CAGR of 6.17%.

Growth is supported by improving hospital oxygen infrastructure and respiratory-care access. Demand remains concentrated in public and private urban hospitals, while price-sensitive procurement and dependence on imported devices favour suppliers with strong local distribution.

 

Middle East and Africa Develop with Oxygen Infrastructure

The Middle East and Africa accounted for 5.0% of the market in 2025, valued at USD 0.0240 billion. The region is expected to reach USD 0.0365 billion by 2032 at a CAGR of 6.17%.

Gulf countries have advanced hospitals, while many African health systems still face oxygen-access, power and distribution constraints. Market expansion depends on investment in oxygen plants, concentrators and cylinders because these systems create follow-on demand for masks, cannulas and tubing.

 

Competitive Landscape: Contract-Driven Rivalry in Oxygen Delivery Systems

The market is moderately fragmented, with global distributors, respiratory-product manufacturers and regional suppliers competing on accuracy, comfort, price and supply reliability. Competition is concentrated in the disposable segment, which represents 72.0% of 2025 revenue, and in hospitals and clinics, which account for 58.0% of end-user demand.

Medline strengthens its position through the Hudson RCI Multi-Vent range and a broad portfolio covering tubing, cannulas, nebulisers and humidification products. SunMed expanded through the 2023 acquisition of Vyaire Medical’s consumables business, adding AirLife oxygen-therapy products and improving its competitiveness in multi-product tenders. Intersurgical differentiates through fixed and adjustable Venturi systems and its non-PVC EcoLite range.

Regional manufacturers compete mainly on price, local availability and private-label production. Their strongest opportunities are in Asia-Pacific, which is growing at 7.97%, and in Latin America and the Middle East and Africa, both expanding at 6.17%. Suppliers are evaluated on oxygen accuracy, colour coding, adult and paediatric options, comfort, packaging, supply continuity and tender pricing.

Venturi masks also compete with nasal cannulas, non-rebreathing masks and high-flow systems. They remain most relevant when precise, moderate oxygen delivery is required without advanced equipment, while their role is more limited in routine low-acuity homecare and high-acuity respiratory support.

 

Analyst Perspective

The Venturi masks market will remain a steady, high-volume respiratory-consumables segment. Disposable masks will retain leadership from their 72.0% share and USD 0.3456 billion 2025 revenue, reaching USD 0.5475 billion by 2032. Reusable products will grow more slowly at 4.47%.

COPD will remain the largest application with a 37.0% share, while postoperative oxygen therapy will be the fastest-growing application at 7.97%. Hospitals and clinics will remain the largest end users with a 58.0% share, while homecare will expand fastest at 8.54%.

North America will remain the largest market with a 36.0% share, while Asia-Pacific will grow the fastest at a 7.97% CAGR. Demand will be driven by accurate oxygen delivery, simple product design, and reliable supply. Large companies compete through wide product portfolios and strong distribution, while regional players focus on lower prices and availability. Clinical guidelines continue to support Venturi mask use, but alternatives like nasal cannulas and high-flow systems limit demand to patients needing controlled, fixed oxygen concentrations.

 

Venturi Masks Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 0.48 Billion
Revenue Forecast in 2032	USD 0.73 Billion
Overall Growth Rate	CAGR of 6.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Disposable Venturi Masks, Reusable Venturi Masks
By Application	Chronic Obstructive Pulmonary Disease, Asthma, Pneumonia, Postoperative Oxygen Therapy, Other Respiratory Conditions
By End User	Hospitals and Clinics, Ambulatory Surgical Centers, Homecare Settings, Emergency Medical Services
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising COPD prevalence and respiratory disease burden, increasing demand for controlled oxygen delivery systems, growth in postoperative and homecare oxygen therapy, expansion of hospital and emergency respiratory-care infrastructure
Customization Option	Available upon request